Arcellx (ACLX) Competitors

Genmab A/S (NASDAQ:GMAB) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Do analysts rate GMAB or ACLX?

Genmab A/S presently has a consensus price target of $39.17, indicating a potential upside of 90.68%. Arcellx has a consensus price target of $110.67, indicating a potential upside of 73.00%. Given Genmab A/S's higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Arcellx	0 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.14

Do insiders and institutionals have more ownership in GMAB or ACLX?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 6.2% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media favor GMAB or ACLX?

In the previous week, Genmab A/S had 8 more articles in the media than Arcellx. MarketBeat recorded 13 mentions for Genmab A/S and 5 mentions for Arcellx. Arcellx's average media sentiment score of 1.76 beat Genmab A/S's score of 0.45 indicating that Arcellx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcellx	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk & volatility, GMAB or ACLX?

Genmab A/S has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Which has higher valuation & earnings, GMAB or ACLX?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.63	$1.14B	$1.74	11.80
Arcellx	$107.94M	32.56	-$70.69M	-$2.00	-31.99

Does the MarketBeat Community prefer GMAB or ACLX?

Genmab A/S received 99 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
Arcellx	Outperform Votes 68 82.93%	Underperform Votes 14 17.07%

Is GMAB or ACLX more profitable?

Genmab A/S has a net margin of 36.30% compared to Arcellx's net margin of -25.94%. Genmab A/S's return on equity of 16.78% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Arcellx	-25.94%	-8.28%	-5.21%

Summary

Genmab A/S beats Arcellx on 11 of the 19 factors compared between the two stocks.